Cantargia, a biopharma spin-out of Lund University, raises SEK 7m from Sunstone Capital and LU Bioscience to fight leukaemia.
Lund University spin-out Cantargia, which is development therapeutics to treat leukaemia, has raised SEK 7m ($1m).
Venture firm Sunstone Capital invested €500k ($638k) in the Sweden-based biopharmaceutical firm, and LU Bioscience (LUBio), a holding company partially owned (20%) by Lund University, made up the difference with a further SEK 3m. Following the investment, Sunstone and LUBio will own 8% and 5% of Cantargia respectively.
Remaining shares in the firm are owned by the company founders, life science firm Innovagen, and…
